Post-IPO Debt - ADMA Biologics
Investment Firm
Overview
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
Announced Date
Oct 11, 2017
Funding Type
Post Ipo Debt
Highlights
Location
United States, North America
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 Marathon Asset Management |
Round Details and Background
ADMA Biologics raised $30000000 on 2017-10-11 in Post-IPO Debt
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
Company Funding History
16
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Dec 18, 2023 |  Post-IPO Debt - ADMA Biologics | 1 | - | 135.0M |
| Feb 13, 2012 | Venture Round - ADMA Biologics | 3 | - | 17.5M |
| Dec 15, 2014 | Post-IPO Debt - ADMA Biologics | 1 | - | 5.0M |
| Feb 27, 2014 | Post-IPO Debt - ADMA Biologics | 1 | - | 15.0M |
Recent Activity
There is no recent news or activity for this profile.